Head-to-head evidence
Risperidone (QUAR) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Risperidone (QUAR)
Developed by Laboratorios Farmacéuticos Rovi, S.A.
NCT06276361 · Phase 1 · completed
A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Ziprasidone
Marketed by Pfizer and partners
NCT00159770 · Phase 3 · completed
The study used randomization and active comparators but was open-label, with 290 participants, and its primary clinical endpoint was PANSS symptom change. No results are posted, so the primary endpoint cannot be classified as met or missed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Risperidone (QUAR)'s landscape · Ziprasidone's landscape